GlassScriptPhysician profile
Cynthera Mcneill
NPI 1770904831
$8,666.88
in general payments reported to CMS, 2019-2025
28 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 85% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,734 · 2022: $1,121 · 2023: $1,365 · 2024: $1,427 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $2,620.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $813.76 | 2021-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $792.26 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $501.94 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Medtronic, INC. | $405.43 | 2023-2025 | Interstim |
| Teva Pharmaceuticals USA, INC. | $395.64 | 2021-2025 | Uzedy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $351.81 | 2022-2024 | |
| Amgen INC. | $269.73 | 2023-2024 | Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $249.92 | 2022-2025 | Breztri |
| Novo Nordisk INC | $244.06 | 2022-2025 | Ozempic |
| Abbvie INC. | $207.35 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $172.69 | 2021-2025 | |
| Abiomed | $139.15 | 2024 | Impella |
| Alkermes, INC. | $124.74 | 2025 | Lybalvi |
| Biohaven Pharmaceuticals, INC. | $123.08 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $122.10 | 2021 | |
| Eisai INC. | $121.16 | 2025 | |
| Phathom Pharmaceuticals, INC. | $116.10 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $115.42 | 2023 | Quviviq |
| Lundbeck LLC | $115.00 | 2023 | Vyepti |
| Boston Scientific Corporation | $113.43 | 2021-2022 | |
| Urovant Sciences INC | $110.13 | 2021 | |
| Astellas Pharma US INC | $104.31 | 2024 | Veozah |
| Alnylam Pharmaceuticals INC. | $97.15 | 2024 | Onpattro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.73 | 2023 | |
| Cmp Pharma, INC. | $63.09 | 2022 | |
| Molnlycke Health Care US, LLC | $45.63 | 2023 | Mepilex Border Sacrum, Mepilex, Mepilex Border Flex |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthera Mcneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.